Rogco LP Has $480,000 Holdings in Pfizer Inc. $PFE

Rogco LP increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.8% during the second quarter, HoldingsChannel reports. The fund owned 19,815 shares of the biopharmaceutical company’s stock after buying an additional 539 shares during the period. Rogco LP’s holdings in Pfizer were worth $480,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the first quarter worth about $27,000. North Capital Inc. bought a new stake in Pfizer in the 1st quarter valued at approximately $28,000. Bayforest Capital Ltd bought a new stake in Pfizer in the 1st quarter valued at approximately $28,000. Horizon Financial Services LLC acquired a new position in Pfizer during the 1st quarter worth approximately $35,000. Finally, WPG Advisers LLC bought a new position in shares of Pfizer during the 1st quarter worth approximately $35,000. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.12.

Pfizer Trading Up 6.8%

Pfizer stock opened at $25.46 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a 50-day simple moving average of $24.55 and a 200 day simple moving average of $24.11. The stock has a market capitalization of $144.75 billion, a P/E ratio of 13.54, a PEG ratio of 0.77 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the company posted $0.60 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.